Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial

JACC: Cardiovascular Interventions

Volumn 3, Issue 8, 2010, Pages 796-802

  Parodi, Guido ^a   Antoniucci, David ^a   Nikolsky, Eugenia ^b   Witzenbichler, Bernhard ^c   Guagliumi, Giulio ^d   Peruga, Jan Z ^e   Stuckey, Thomas ^f   Dudek, Darius ^g   Kornowski, Ran ^h   Hartmann, Franz ⁱ   Lansky, Alexandra J ^b   Mehran, Roxana ^b   Stone, Gregg W ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NewYork Presbyterian Hospital   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d OSPEDALI RIUNITI   (Italy)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f MOSES CONE HEALTH SYSTEM   (United States)

^g JAGIELLONIAN UNIVERSITY   (Poland)

^h RABIN MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

acute myocardial infarction; angioplasty; bivalirudin; bleeding; mortality; risk score; stent

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; HIRULOG; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HEMORRHAGE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 78651270461     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.05.009     Document Type: Article

References (14)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
2. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-65.
3. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28:443-9.
4. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-82.
5. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 2007;49:1362-8.
6. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
7. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59.
8. Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 2008;156:44-56.
9. Halkin A, Singh M, Nicolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction. The CADILLAC risk score. J Am Coll Cardiol 2005;45:1397-405.
10. Lev EI, Kornowski R, Vaknin-Assa H, et al. Comparison of the predictive value of four different risk scores for outcome of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2008;102:6-11.
11. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein blockade compared with heparin and planned glycoprotein blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
12. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19.
13. Parodi G, Migliorini A, Valenti R, et al. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Car-diol 2010;105:1053-9.
14. Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation on patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008;29:1504-9.